Literature DB >> 29559751

Circulating and Urinary miR-210 and miR-16 Increase during Cardiac Surgery Using Cardiopulmonary Bypass - A Pilot Study.

Annette L Mazzone1,2, Robert A Baker1,2, Kym McNicholas2,3, Richard J Woodman4, Michael Z Michael2,5, Jonathan M Gleadle2,3.   

Abstract

A pilot study to measure and compare blood and urine microRNAs miR-210 and miR-16 in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) and off-pump coronary artery bypass grafting surgery. Frequent serial blood and urine samples were taken from patients undergoing cardiac surgery with CPB (n = 10) and undergoing off-pump cardiac surgery (n = 5) before, during, and after surgery. Circulating miR-210 and miR-16 levels were determined by relative quantification real-time polymerase chain reaction. Levels of plasma-free haemoglobin (fHb), troponin-T, creatine kinase, and creatinine were measured. Perioperative serum miR-210 and miR-16 were elevated significantly compared to preoperative levels in patients undergoing cardiac surgery with CPB (CPB vs. Pre Op and Rewarm vs. Pre Op; p < .05 for both). There were increases of greater than 200% in miR-210 levels during rewarming and immediately postoperatively and a 3,000% increase in miR-16 levels immediately postoperatively in urine normalized to urinary creatinine concentration. Serum levels of miR-16 were relatively constant during off-pump surgery. miR-210 levels increased significantly in off-pump patients perioperatively (p < .05 Octopus on vs. Pre Op); however, the release was less marked when compared to cardiac surgery with CPB. A significant association was observed between both miR-16 and miR-210 and plasma fHb when CPB was used (r = -.549, p < .0001 and r = -.463, p < .0001 respectively). Serum and urine concentrations of hypoxically regulated miR-210 and hemolysis-associated miR-16 increased in cardiac surgery using CPB compared to off-pump surgery. These molecules may have utility in indicating severity of cardiac, red cell, and renal injury during cardiac surgery.

Entities:  

Keywords:  cardiac surgery; cardiopulmonary bypass; hemolysis; hypoxia; microRNA

Mesh:

Substances:

Year:  2018        PMID: 29559751      PMCID: PMC5848080     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  25 in total

1.  Circulating miR-210 predicts survival in critically ill patients with acute kidney injury.

Authors:  Johan M Lorenzen; Jan T Kielstein; Carsten Hafer; Shashi K Gupta; Philipp Kümpers; Robert Faulhaber-Walter; Hermann Haller; Danilo Fliser; Thomas Thum
Journal:  Clin J Am Soc Nephrol       Date:  2011-06-23       Impact factor: 8.237

2.  MicroRNA-210 as a novel therapy for treatment of ischemic heart disease.

Authors:  Shijun Hu; Mei Huang; Zongjin Li; Fangjun Jia; Zhumur Ghosh; Maarten A Lijkwan; Pasquale Fasanaro; Ning Sun; Xi Wang; Fabio Martelli; Robert C Robbins; Joseph C Wu
Journal:  Circulation       Date:  2010-09-14       Impact factor: 29.690

3.  microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects.

Authors:  R Kannan Mutharasan; Varun Nagpal; Yoshihiko Ichikawa; Hossein Ardehali
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-12       Impact factor: 4.733

Review 4.  miR-210: the master hypoxamir.

Authors:  Yuk C Chan; Jaideep Banerjee; Sang Yong Choi; Chandan K Sen
Journal:  Microcirculation       Date:  2012-04       Impact factor: 2.628

5.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

6.  Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery.

Authors:  Won K Han; Gebhard Wagener; Yanqing Zhu; Shuang Wang; H Thomas Lee
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

7.  Myocardial injury after off-pump coronary artery bypass grafting operation.

Authors:  Domenico Paparella; Giangiuseppe Cappabianca; Piergiorgio Malvindi; Andreas Paramythiotis; Antonella Galeone; Nicola Veneziani; Corrado Fondacone; Luigi de Luca Tupputi Schinosa
Journal:  Eur J Cardiothorac Surg       Date:  2007-07-23       Impact factor: 4.191

8.  Off-pump coronary surgery causes immediate release of myocardial damage markers.

Authors:  Inga Karu; Peeter Tähepõld; Toomas Andres Sulling; Margus Alver; Mihkel Zilmer; Joel Starkopf
Journal:  Asian Cardiovasc Thorac Ann       Date:  2009-10

9.  The Impact of Hemolysis on Cell-Free microRNA Biomarkers.

Authors:  Michaela B Kirschner; J James B Edelman; Steven C-H Kao; Michael P Vallely; Nico van Zandwijk; Glen Reid
Journal:  Front Genet       Date:  2013-05-24       Impact factor: 4.599

10.  Hemolysis during cardiac surgery is associated with increased intravascular nitric oxide consumption and perioperative kidney and intestinal tissue damage.

Authors:  Iris C Vermeulen Windsant; Norbert C J de Wit; Jonas T C Sertorio; Annemarie A van Bijnen; Yuri M Ganushchak; John H Heijmans; Jose E Tanus-Santos; Michael J Jacobs; Jos G Maessen; Wim A Buurman
Journal:  Front Physiol       Date:  2014-09-08       Impact factor: 4.566

View more
  2 in total

Review 1.  A narrative review of the roles of the miR-15/107 family in heart disease: lessons and prospects for heart disease.

Authors:  Manni Zheng; Min Wang
Journal:  Ann Transl Med       Date:  2021-01

2.  microRNA Expression Levels Change in Neonatal Patients During and After Exposure to Cardiopulmonary Bypass.

Authors:  Lance Hsieh; Lan N Tu; Alison Paquette; Quanhu Sheng; Shilin Zhao; Douglas Bittel; James O'Brien; Kasey Vickers; Peter Pastuszko; Vishal Nigam
Journal:  J Am Heart Assoc       Date:  2022-08-24       Impact factor: 6.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.